Drugs / LY3114062
last change Jun 2015 re-read 3 minutes ago

LY3114062

Developed for
arthritic joint disease
Investigated by
Eli Lilly and Company

Trials 1

2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02144272 Jun 2014 → May 2015 arthritic joint disease Eli Lilly and Company Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as LY3114062 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02144272 ↗
Route Subcutaneous “LY3114062 administered SC.” NCT02144272 ↗